Emergent BioSolutions Inc.
Price Action
Technical Summary
CONSOLIDATINGEmergent BioSolutions Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 34), showing significant lag compared to the market leaders. Earnings contraction of 76% provides fundamental context to the price action. Investors should exercise caution due to high volatility (92% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.42 | +8.44% | ABOVE |
| 50 SMA | $8.38 | +9.02% | ABOVE |
| 100 SMA | $10.10 | -9.53% | BELOW |
| 150 SMA | $10.18 | -10.22% | BELOW |
| 200 SMA | $9.64 | -5.21% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is EBS in an uptrend right now?
EBS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is EBS overbought or oversold?
EBS's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is EBS outperforming the market?
EBS has a Relative Strength (RS) Rating of 34 out of 99. EBS is currently lagging the broader market.
Where is EBS in its 52-week range?
EBS is trading at $9.13, which is 65% of its 52-week high ($14.06) and 47% above its 52-week low ($4.72).
How volatile is EBS?
EBS has a Beta of 1.83 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.